QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.104.001222v1 33/1/175    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maurer, T. S. Articles by Scott, D. O. Search for Related Content PubMed PubMed Citation Articles by Maurer, T. S. Articles by Scott, D. O.

RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE

Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, Connecticut

(Received June 29, 2004; accepted October 20, 2004)

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Unbound fractions in mouse brain and plasma were determined for 31 structurally diverse central nervous system (CNS) drugs and two active metabolites. Three comparisons were made between in vitro binding and in vivo exposure data, namely: 1) mouse brain-to-plasma exposure versus unbound plasma-to-unbound brain fraction ratio (fu_plasma/fu_brain), 2) cerebrospinal fluid-to-brain exposure versus unbound brain fraction (fu_brain), and 3) cerebrospinal fluid-to-plasma exposure versus unbound plasma fraction (fu_plasma). Unbound fraction data were within 3-fold of in vivo exposure ratios for the majority of the drugs examined (i.e., 22 of 33), indicating a predominately free equilibrium across the blood-brain and blood-CSF barriers. Some degree of distributional impairment at either the blood-CSF or the blood-brain barrier was indicated for 8 of the 11 remaining drugs (i.e., carbamazepine, midazolam, phenytoin, sulpiride, thiopental, risperidone, 9-hydroxyrisperidone, and zolpidem). In several cases, the indicated distributional impairment is consistent with other independent literature reports for these drugs. Through the use of this approach, it appears that most CNS-active agents freely equilibrate across the blood-brain and blood-CSF barriers such that unbound drug concentrations in brain approximate those in the plasma. However, these results also support the intuitive concept that distributional impairment does not necessarily preclude CNS activity.

(1)

Following this expectation, attempts have been made to predict tissue partitioning from in vitro estimates of unbound plasma fraction and unbound tissue fraction with mixed success (Bickel and Gerny, 1980; Bickel et al., 1987; Schuhmann et al., 1987; Clausen and Bickel, 1993). Previous reports suggest that the dilution, homogenization, and incubation process necessary to determine unbound tissue fraction by equilibrium dialysis may disrupt or destroy intracellular components that contribute to distribution in vivo. For example, it has been suggested that disruption of the postnuclear fractions containing the acidic organelles (e.g., lysosomes) may explain reported under-predictions in the distribution of the basic lipophilic drugs imipramine, desipramine, chlorpromazine, and methadone from liver, lung, and kidney homogenates (Clausen and Bickel, 1993). Further supporting this hypothesis, accurate predictions have been reported for acidic and neutral drugs in these same tissues and also for the same basic lipophilic drugs in tissues with less abundant lysosomes (e.g., brain, muscle, and adipose tissue).

We have recently extended this approach to provide an indirect determination of brain penetration (Kalvass and Maurer, 2002). In the event that a drug freely diffuses across the blood-brain and blood-CSF barriers, it is reasonable to expect that CSF concentrations will be reflective of those in the brain extracellular fluid (de Lange and Danhof, 2002). As such, it is also reasonable to expect that the following relationships should be demonstrable for such drugs (A, B and C, below). In these relationships, B/P, CSF/P, and CSF/B represent the in vivo brain-to-plasma, CSF-to-plasma, and CSF-to-brain concentration ratios at equilibrium. Unbound fractions in plasma and brain are represented by fu_plasma and fu_brain, respectively.

(A)

(B)

(C)

Consistent with these expectations, we have previously reported such predictive correlations for nine proprietary CNS compounds for which independent evidence indicated that the prerequisite assumptions regarding blood-brain and blood-CSF barrier diffusion were met (Kalvass and Maurer, 2002). In that work, it was further demonstrated that, as expected, fu_plasma/fu_brain over-predicts the B/P of P-glycoprotein efflux substrates. However, no consistent pattern was observed with regard to the magnitude of disparity in relationships A, B, and C. This latter finding is not surprising given the complex factors governing drug distribution between CSF and extracellular fluid for such compounds (de Lange and Danhof, 2002). However, as suggested previously, patterns of disparity among these relationships for any particular compound may provide additional insight into the nature of the active processes influencing the CNS distribution process. In this work, we sought to demonstrate these relationships among 33 marketed CNS drugs.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Chemicals. Supplies of cyclobenzaprine, fluoxetine, methylphenidate, 9-hydroxyrisperidone, and sertraline were obtained from Pfizer Global Material Management (Groton, CT). Citalopram, lamotrigine, and paroxetine were purchased from Sequoia Research Products (Oxford, UK). The following reagents were purchased from the respective vendors: clozapine (MP Biomedicals, Irvine, CA), fluvoxamine (Tocris Cookson, Ellisville, MO), midazolam (Cerilliant, Round Rock, TX), propoxyphene (U.S. Pharmacopoeia, Rockville, MD), and venlafaxine (Alchemie USA, Plantsville, CT). All other drugs included in the study were purchased from Sigma-Aldrich (St. Louis, MO).

Drug Selection. Drug inclusion and the associated rationales are the same as those used in the accompanying article (Doran et al., 2005). Ethosuxamide was excluded from this analysis due to a lack of analytical sensitivity necessary to estimate unbound plasma and brain fractions.

Animal Exposure Data. B/P, CSF/P, and CSF/B ratios from in vivo studies were obtained from the accompanying article (see Doran et al., 2005). Ratios used in this analysis were derived from the area under the curve measured up to 5 h after a 3 mg/kg subcutaneous dose to male FVB mice (except caffeine, administered at 5 mg/kg).

Nonspecific Binding Studies. A 96-well equilibrium dialysis apparatus was used to determine the plasma and brain free fraction for each drug (Banker et al., 2003). Spectra-Por 2 membranes with molecular cutoff of 12 to 14 kDa, obtained from Spectrum Laboratories Inc. (Rancho Dominguez, CA), were used for the dialysis. The membranes were conditioned in deionized water for 15 min followed by 30% ethanol for 15 min and 0.10 M sodium phosphate pH 7.4 buffer for 15 min. Fresh female FVB (wild-type) mouse blood and brain were obtained the day of the experiment. Fresh FVB mouse plasma and brain tissue was obtained on the day of the study. Brain samples were diluted with 2 volumes of 0.10 M sodium phosphate pH 7.4 buffer and homogenized via ultrasonic probe. Plasma and 1/3 brain homogenate were spiked with the test drug (1000 ng/g) and 150-µl aliquots were loaded into the 96-well equilibrium dialysis plate and dialyzed versus 150 µl of 0.10 M sodium phosphate pH 7.4 buffer. Equilibrium was achieved by incubating the 96-well equilibrium dialysis apparatus for 4.5 h in a 37°C reciprocating water bath (set at 155 rpm). Incubation time was based on prior experience with this system indicating that equilibrium is consistently achieved within 4.5 h (data not shown). After reaching equilibrium, the indicated aliquots of each matrix (Table 1) were taken from the 96-well equilibrium dialysis apparatus and added to HPLC vials containing an equivalent volume of dimethyl sulfoxide and 100 µl of acetonitrile. The appropriate amount of control buffer was added to the plasma and 1/3 brain homogenate samples, and the appropriate amount of either control plasma or control brain homogenate was added to the buffer samples to yield identical matrix between buffer and nonbuffer samples. A standard curve was made up in dimethyl sulfoxide over the concentration range of 1 nM to 2000 nM. The appropriate amount of control buffer and either control plasma or control brain homogenate was added to the standard samples as well as 100 µl of acetonitrile to yield anidentical matrix between samples and standards. The samples and standards were than vortexed and centrifuged, and the supernatant was assayed by liquid chromatography/tandem mass spectrometry. For plasma, the unbound fraction was determined as the ratio of concentrations determined in buffer and plasma. As previously described, the unbound fraction in undiluted brain was calculated via eq. 3, where D and fu_meas represent the fold dilution of brain tissue and the associated free fraction determined as the ratio of concentrations in buffer versus diluted brain tissue (Kalvass and Maurer, 2002).

(3)

Analysis of Drugs in Protein Binding Samples. All samples were quantified using HPLC-MS/MS as summarized in Table 1. Drugs were analyzed using either a PE-Sciex API-3000 triple quadrupole (Turbo Ionspray source 500°C, 81 psi/min nitrogen; PerkinElmerSciex Instruments, Boston, MA) or a PE-Sciex API-4000 triple quadrupole (Turbo V Ionspray source 700°C, 75 psi of nitrogen) mass spectrometer. Samples were injected (3-10 µl) using a CTC Analytics HTS Pal (with a 100-µl syringe) autosampler (CTC Analytics, Zwingen, Switzerland) onto either a Phenomenex Synergi Max-RP 2.0 x 30 mm, 4-µm column (Phenomenex, Torrance, CA) or a Primesphere 5-µm HC-C18 2.0 x 30 mm column (Phenomenex) maintained at 50°C. Analytes were eluted with a high-pressure linear gradient program, produced by two Shimadzu LC-10ADVP binary pumps and a 10-µl static mixer, consisting of methanol (solvent A), 10 mM ammonium acetate (containing 1% 2-propanol), 6.8 pH (solvent B), and acetonitrile (solvent C). The total run time was 3.0 min for drugs run on the API 3000 and 1.5 min for drugs run on the API 4000. For drugs run on the API 3000, the initial mobile phase conditions were held for 0.5 min, ramped to an intermediate condition between 0.5 and 2 min, held there for 0.5 min, then returned to the initial condition in a single step and held there for 0.5 min to allow for re-equilibration prior to the next injection (Table 1). During mobile phase ramping, the flow rate was also ramped from 500 to 750 µl/min. For drugs run on the API 4000, the initial mobile phase conditions were held for 0.25 min, ramped to an intermediate condition between 0.25 and 1.0 min, held there for 0.25 min, then returned to the initial condition in a single step and held there for 0.25 min to allow for reequilibration prior to the next injection (Table 1). During mobile phase ramping, the flow rate was also ramped from 750 to 1500 µl/min. Source parameters were optimized for each drug and were measured using multiple reaction monitoring with either positive or negative ionization. Nonlinear standard curves (quadratic with 1/x² weighting) were used for analysis of the equilibrium dialysis.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Estimates of fu_brain, fu_plasma, and fu_plasma/fu_brain ratio varied by 955-, 102-, and 26-fold, respectively, among the 33 drugs examined (Table 2; Fig. 1). The ranges of fu_plasma estimates were similar between the nine weakly acidic/neutral drugs (i.e., caffeine, carbamazepine, carisoprodol, diazepam, meprobamate, midazolam, phenytoin, thiopental, and zolpidem) and the remaining 24 basic drugs. The most extensive binding to brain tissue was observed among the basic drugs, with several displaying a fu_brain less than 0.01 (i.e., clozapine, fluvoxamine, cyclobenzaprine, haloperidol, nortriptyline, paroxetine, fluoxetine, chlorpromazine, and sertraline). As such, the range of fu_brain estimates was far greater among basic drugs (i.e., 0.00066-0.63) than that observed for the weakly acidic/neutral drugs (i.e., 0.0272-0.52). This, in turn, resulted in a greater range of fu_plasma/fu_brain ratios for basic drugs (0.64-16.7) than was observed for the weakly acidic/neutral drugs (1.00-2.79).

View larger version (15K): [in this window] [in a new window]   FIG. 1. Relationship between brain/plasma ratio and fuplasma/fubrain ratio (A), CSF/brain ratio and fubrain (B), and CSF/plasma ratio and fuplasma (C) for the 33 CNS drugs examined in FVB mice. Solid symbols () represent the mean data observed for the 24 basic CNS drugs. Open symbols () represent the mean data observed for the 9 weakly acidic/neutral CNS drugs. Solid line represents that of unity and dashed lines represent 3-fold boundaries.

Overall, 23 of the examined drugs (i.e., 70%) achieved B/P, CSF/B, and CSF/P exposure ratios that were all within 3-fold of fu_plasma/fu_brain ratio, fu_plasma, and fu_brain, respectively (Fig. 1; Table 3, class 1). Mouse fu_plasma/fu_brain ratios over-predicted B/P ratios by 16-, 6-, and 4-fold for sulpiride, thiopental, and risperidone, respectively (Table 3, class 2). For these drugs, fu_plasma over-predicted CSF/P to a similar degree, whereas fu_brain predicted CSF/B to within 3-fold. Similarly, fu_plasma/fu_brain ratios over-predicted B/P ratios of carbamazepine, midazolam, phenytoin, and zolpidem by 4-, 7-, 4-, and 4-fold, respectively (Table 3, class 3). However, in this case, fu_brain under-predicted CSF/B to a similar degree, whereas fu_plasma predicted CSF/P to within 2-fold. Although the B/P ratios of buspirone and caffeine were predicted to within 2-fold by fu_plasma/fu_brain ratios, fu_plasma and fu_brain over-predicted CSF/P and CSF/B between 5- and 14-fold (Table 3, class 4). The largest over-prediction of B/P by fu_plasma/fu_brain was observed for 9-hydroxyrisperidone (i.e., 64-fold; Table 3, class 4). In this case, fu_plasma over-predicted CSF/P and fu_brain under-predicted CSF/B to a similar extent.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
For purposes of discussion, drugs were grouped into one of four general patterns of behavior that were observed when comparing unbound fraction data with in vivo exposure ratios (Table 3). Unbound fraction data were considered to be predictive of in vivo exposure ratios if the two values were within 3-fold. This criterion was chosen to allow for differences due to random experimental error and for actual differences that would be considered to be of little pharmacologic or pharmacokinetic consequence. The drugs falling into the four general classes of behavior and the implications of that behavior are discussed below.

Class 1. The majority of the drugs studied (23 of 33) followed a pattern of behavior in which fu_brain, fu_plasma, and fu_plasma/fu_brain ratios were predictive of CSF/B, CSF/P, and B/P, respectively (Table 3). Since this pattern would be expected under conditions in which a drug freely diffuses across both the blood-brain and blood-CSF barriers, the fact that the majority of the studied CNS drugs fall into this classification is not surprising. These results indicate that despite the greater than 50-fold range in absolute brain-to-plasma exposure ratios, free drug exposures in plasma and brain are equivalent for the drugs in this class. In other words, the large differences in brain-to-plasma ratio observed among these drugs are determined by differences in relative nonspecific plasma and tissue binding, not blood-brain barrier penetration. These results highlight the potential pitfalls of approaches that are associated with the implicit assumption that larger B/P values are indicative of a greater degree of brain penetration (Lombardo et al., 1996; Salminen et al., 1997; Norinder et al., 1998; Clark, 1999; Luco, 1999; Feher et al., 2000; Kaznessis et al., 2001; Keseru and Molnar, 2001; Platts et al., 2001). Because B/P is determined largely by nonspecific binding, efforts to optimize this parameter may actually lead to an unproductive or counterproductive design of drugs that are unnecessarily basic, lipophilic, and simply have a greater degree of nonspecific partitioning into brain tissue.

Class 2. Risperidone, sulpiride, and thiopental followed a pattern of behavior in which fu_brain was predictive of CSF/B, whereas fu_plasma and fu_plasma/fu_brain over-predicted CSF/P and B/P to a similar extent (Table 3). This pattern would be expected in the presence of a similar degree of impairment in diffusion across the blood-brain and blood-CSF barriers. In such an event, CSF exposure would fall short of free plasma exposure but would be equivalent to free brain exposure. Consistent with this scenario, the polar surface areas of sulpiride (110 Ų) and thiopental (90 Ų) are outside the 95% confidence interval of polar surface areas determined for the 22 drugs in class 1 (i.e., 30-50 Ų) and class 3 (i.e., 29-61 Ų) (Ertl et al., 2000). These values are also above the upper limits for optimal CNS penetration that have been suggested from the examination of large numbers of CNS drugs that have reached phase II efficacy studies (van de Waterbeemd et al., 1998; Ertl et al., 2000). It is important to note, however, that if the disparity between unbound fraction and in vivo exposure is attributable to less than optimal tissue diffusion, then equilibrium in unbound drug concentrations may simply be delayed. As such, the truncated 5-h brain, plasma, and CSF area under the curve estimates used herein may not accurately reflect the concentration ratios that would be achieved for these drugs under equilibrium conditions. Such a delayed equilibrium has been previously reported from microdialysis studies on thiopental (Mather et al., 2000). The other drug in this class, risperidone, also has a reasonably high polar surface area (64 Ų) as compared with the drugs in the other classes and is also now known to be a P-glycoprotein efflux substrate (see Doran et al., 2005). As such, a combination of less than optimal transcellular diffusion and blood-brain barrier efflux may be responsible for its behavioral pattern being borderline between class 2 and class 3.

Class 3. Similar to those in class 2, fu_plasma/fu_brain over-predicted B/P for drugs in this class. In contrast, fu_brain under-predicted CSF/B, whereas fu_plasma was predictive of CSF/P. In each case, the fold over-prediction of B/P was similar to the fold under-prediction of CSF/B. This pattern would be expected in the presence of a distributional impairment that is specific to the blood-brain barrier. In such an event, CSF may accurately reflect free plasma concentrations while providing an overestimation of drug concentrations in the extracellular fluid of the brain. Consistent with the blood-brain barrier impairment implied by these data, increases in the brain extracellular fluid levels of both carbamazepine and phenytoin have been reported in the presence of the MRP inhibitor probenecid and/or in MRP2-deficient TR^- rats (Potschka et al., 2001, 2003; Potschka and Loscher, 2001; Loscher and Potschka, 2002) despite equivalent free plasma and CSF concentrations of these drugs in rats (Chou and Levy, 1981; Sokomba et al., 1988). In both cases, the observed impairment attributed to MRP2 efflux at the blood-brain barrier was enough to account for the differences between the unbound fractions and in vivo exposures reported in this analysis.

In the case of midazolam, further application of this approach to rats suggests that the detected blood-brain barrier impairment may be unique to mice. For example, the unbound fractions of midazolam in mouse and Sprague-Dawley rat plasma are very similar at 0.046 ± 0.004 and 0.0357 ± 0.0010, respectively. The unbound fractions of midazolam in mouse and rat brain are also very similar at 0.0272 ± 0.0018 and 0.0219 ± 0.0014, respectively. As such, the mouse and rat brain-to-plasma ratios predicted by these unbound fractions are very similar at 1.69 ± 0.08 and 1.63 ± 0.05, respectively. However, the actual in vivo B/P estimates of midazolam in mice and rats are approximately 10-fold different at 0.23 (Table 2) and 2.3 (Arendt et al., 1987; Mandema et al., 1992). These data together indicate that the B/P in rats is governed primarily by nonspecific binding, whereas some additional and limiting factor limits the brain partitioning of this drug in mice.

Unlike midazolam, the B/P of zolpidem is very similar between mice (Table 2) and rats (Garrigou-Gadenne et al., 1991). Therefore, it seems unlikely that the impairment in blood-brain barrier penetration implicated by unbound fraction data is unique to the mouse. It is also unlike carbamazepine and phenytoin in that a blood-brain barrier efflux mechanism has not been identified for this drug. Further investigation will be required to understand the underlying mechanism responsible for its pattern of behavior matching the other drugs in this classification.

Class 4. Drugs in this class followed a pattern of behavior that suggests a complex equilibrium between drug concentrations in the CSF and extracellular fluid of the brain. For example, the B/P ratios of buspirone and caffeine were very accurately predicted by fu_plasma/fu_brain, whereas CSF/P and CSF/B were over-predicted to a similar degree by fu_plasma and fu_brain (Table 3). In the case of 9-hydroxyrisperidone, fu_plasma/fu_brain over-predicted B/P by 64-fold. This impairment is qualitatively consistent with the 17-fold difference in B/P ratios between FVB and MDR1a/1b (-/-, -/-) mice. Because the absolute B/P in FVB mice approximated the fractional blood volume of the brain (5%), the latter estimate of impairment may represent an underestimate and highlights one of the limitations of the MDR1a/1b (-/-, -/-) mouse model (see Doran et al., 2005). As with buspirone and caffeine, a simple relationship between the over-prediction of B/P ratio and the over- or under-predictions of CSF/B and CSF/P was not evident.

In summary, these findings illustrate that the B/P ratio of the examined CNS drugs is largely determined by unbound plasma and brain fraction, both of which can be accurately estimated from equilibrium dialysis studies. Several of the examined drugs with disparities between B/P and fu_plasma/fu_brain of greater than 3-fold are known to have additional properties that are expected to influence brain distribution (e.g., high polar surface area, and/or efflux). These findings are also consistent with previous reports that CSF exposures do not necessarily reflect free brain exposure (e.g., classes 3 and 4 in Table 3). Lastly, these results support our previous assertions that unbound plasma and tissue fractions can be used as a model for examining brain penetration. In contrast to transgenic models, this approach is neither mechanism- nor species-specific. As such, it is particularly useful in drug discovery programs pursuing CNS targets.

	Acknowledgments

 
We thank Angela Doran et al. (authors of accompanying article in this issue) for providing the in vivo exposure data necessary to support this analysis. We also thank Drs. Bill Smith, Marcel Hop, Theresa Wilson, and James Baxter for support of this project.

	Footnotes

 
doi:10.1124/dmd.104.001222.

ABBREVIATIONS: CSF, cerebrospinal fluid; B/P, brain-to-plasma drug concentration ratio, CSF/P, cerebrospinal fluid-to-plasma drug concentration ratio; CSF/B, cerebrospinal fluid-to-brain drug concentration ratio; CNS, central nervous system; HPLC, high-performance liquid chromatography.

Address correspondence to: Tristan S. Maurer, Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Pfizer Global Research and Development, Groton Laboratories, Groton, CT 06340. E-mail: tristan_s_maurer{at}groton.pfizer.com

	References

Top Abstract Materials and Methods Results Discussion References

 


Arendt RM, Greenblatt DJ, Liebisch DC, Luu MD, and Paul SM (1987) Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology (Berl) 93: 72-76.[CrossRef][Medline]

Banker MJ, Clark TH, and Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92: 967-974.[CrossRef][Medline]

Bickel MH and Gerny R (1980) Drug distribution as a function of binding competition. Experiments with the distribution dialysis technique. J Pharm Pharmacol 32: 669-674.[Medline]

Bickel MH, Raaflaub RM, Hellmuller M, and Stauffer EJ (1987) Characterization of drug distribution and binding competition by two-chamber and multi-chamber distribution dialysis. J Pharm Sci 76: 68-74.[CrossRef][Medline]

Chou RC and Levy G (1981) Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats. J Pharmacol Exp Ther 219: 42-48.[Abstract/Free Full Text]

Clark DE (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J Pharm Sci 88: 815-821.[CrossRef][Medline]

Clausen J and Bickel MH (1993) Prediction of drug distribution in distribution dialysis and in vivo from binding to tissues and blood. J Pharm Sci 82: 345-349.[CrossRef][Medline]

de Lange EC and Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41: 691-703.[CrossRef][Medline]

Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33: 165-174.[Abstract/Free Full Text]

Ertl P, Rohde B, and Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43: 3714-3717.[CrossRef][Medline]

Feher M, Sourial E, and Schmidt JM (2000) A simple model for the prediction of blood-brain partitioning. Int J Pharm 201: 239-247.[CrossRef][Medline]

Fichtl B, v. Nieciecki A and Walter K (1991) Tissue binding versus plasma binding of drugs: general principles and pharmacokinetic consequences. Adv Drug Res 20: 117-166.

Garrigou-Gadenne D, Durand A, Thenot JP and Morselli PL (1991) The disposition and pharmacokinetics of alpidem, a new anxiolytic, in the rat. Drug Metab Dispos 19: 574-579.[Abstract]

Gibaldi M and McNamara PJ (1978) Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol 13: 373-380.[CrossRef][Medline]

Gillette JR (1971) Factors affecting drug metabolism. Ann NY Acad Sci 179: 43-66.[CrossRef][Medline]

Hanada K, Akimoto S, Mitsui K, Mihara K, and Ogata H (1998) Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding. Pharm Res (NY) 15: 1250-1256.

Honegger UE, Roscher AA, and Wiesmann UN (1983) Evidence for lysosomotropic action of desipramine in cultured human fibroblasts. J Pharmacol Exp Ther 225: 436-441.[Abstract/Free Full Text]

Ishizaki J, Yokogawa K, Nakashima E, Ohkuma S, and Ichimura F (1998a) Characteristic subcellular distribution, in brain, heart and lung, of biperiden, trihexyphenidyl and (-)quinuclidinyl benzylate in rats. Biol Pharm Bull 21: 67-71.[Medline]

Ishizaki J, Yokogawa K, Nakashima E, Ohkuma S, and Ichimura F (1998b) Influence of ammonium chloride on the tissue distribution of anticholinergic drugs in rats. J Pharm Pharmacol 50: 761-766.[Medline]

Ishizaki J, Yokogawa K, Nakashima E, Ohkuma S, and Ichimura F (1998c) Uptake of basic drugs into rat lung granule fraction in vitro. Biol Pharm Bull 21: 858-861.[Medline]

Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23: 327-338.[CrossRef][Medline]

Kaznessis YN, Snow ME, and Blankley CJ (2001) Prediction of blood-brain partitioning using Monte Carlo simulations of molecules in water. J Comput-Aided Mol Des 15: 697-708.[CrossRef]

Keseru GM and Molnar L (2001) High-throughput prediction of blood-brain partitioning: a thermodynamic approach. J Chem Inf Comput Sci 41: 120-128.[CrossRef][Medline]

Kurz H and Fichtl B (1983) Binding of drugs to tissues. Drug Metab Rev 14: 467-510.[Medline]

Larsson B and Tjalve H (1979) Studies on the mechanism of drug-binding to melanin. Biochem Pharmacol 28: 1181-1187.[CrossRef][Medline]

Lombardo F, Blake JF, and Curatolo WJ (1996) Computation of brain-blood partitioning of organic solutes via free energy calculations. J Med Chem 39: 4750-4755.[CrossRef][Medline]

Loscher W and Potschka H (2002) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301: 7-14.[Abstract/Free Full Text]

Luco JM (1999) Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling. J Chem Inf Comput Sci 39: 396-404.[CrossRef][Medline]

MacIntyre AC and Cutler DJ (1988) The potential role of lysosomes in tissue distribution of weak bases. Biopharm Drug Dispos 9: 513-526.[CrossRef][Medline]

Mandema JW, Kuck MT, and Danhof M (1992) Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship. Br J Pharmacol 105: 164-170.[Medline]

Mather LE, Edwards SR, Duke CC, and Cousins MJ (2000) Microdialysis study of the blood-brain equilibration of thiopental enantiomers. Br J Anaesth 84: 67-73.[Abstract/Free Full Text]

Nishiura A, Higashi J, Murakami T, Higashi Y, and Yata N (1986) A possible contribution of phospholipids in tissue distribution of quinidine in rats. J Pharmacobio-Dyn 9: 819-828.[Medline]

Nishiura A, Murakami T, Higashi Y, and Yata N (1987) Role of acidic phospholipids in tissue distribution of quinidine in rats. J Pharmacobio-Dyn 10: 134-141.[Medline]

Nishiura A, Murakami T, Higashi Y, and Yata N (1988) Role of phosphatidylserine in the cellular and subcellular lung distribution of quinidine in rats. Pharm Res (NY) 5: 209-213.

Norinder U, Sjoberg P, and Osterberg T (1998) Theoretical calculation and prediction of brain-blood partitioning of organic solutes using MolSurf parametrization and PLS statistics. J Pharm Sci 87: 952-959.[CrossRef][Medline]

Platts JA, Abraham MH, Zhao YH, Hersey A, Ijaz L, and Butina D (2001) Correlation and prediction of a large blood-brain distribution data set—an LFER study. Eur J Med Chem 36: 719-730.[CrossRef][Medline]

Potschka H, Fedrowitz M, and Loscher W (2001) P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12: 3557-3560.[CrossRef][Medline]

Potschka H, Fedrowitz M, and Loscher W (2003) Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 306: 124-131.[Abstract/Free Full Text]

Potschka H and Loscher W (2001) Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 12: 2387-2389.[CrossRef][Medline]

Salminen T, Pulli A, and Taskinen J (1997) Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. J Pharm Biomed Anal 15: 469-477.[CrossRef][Medline]

Schuhmann G, Fichtl B, and Kurz H (1987) Prediction of drug distribution in vivo on the basis of in vitro binding data. Biopharm Drug Dispos 8: 73-86.[CrossRef][Medline]

Sokomba EN, Patsalos PN, Lolin YI, and Curzon G (1988) Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid. Neuropharmacology 27: 409-415.[CrossRef][Medline]

Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, and Sugiyama Y (2002) Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. Drug Metab Dispos 30: 1393-1399.[Abstract/Free Full Text]

van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, and Raevsky OA (1998) Estimation of blood-brain barrier crossing of drugs using molecular size and shape and H-bonding descriptors. J Drug Target 6: 151-165.[Medline]

Wierzba K, Sugiyama Y, Okudaira K, Iga T, and Hanano M (1987) Tubulin as a major determinant of tissue distribution of vincristine. J Pharm Sci 76: 872-875.[Medline]

Wilkinson GR and Shand DG (1975) Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377-390.[Medline]

Xie X, Steiner SH, and Bickel MH (1991) Kinetics of distribution and adipose tissue storage as a function of lipophilicity and chemical structure. II. Benzodiazepines. Drug Metab Dispos 19: 15-19.[Abstract]

Yata N, Toyoda T, Murakami T, Nishiura A, and Higashi Y (1990) Phosphatidylserine as a determinant for the tissue distribution of weakly basic drugs in rats. Pharm Res (NY) 7: 1019-1025.

Yoshida H, Kamiya A, Okumura K, and Hori R (1989) Contribution of monoamine oxidase (MAO) to the binding of tertiary basic drugs in lung mitochondria. Pharm Res (NY) 6: 877-882.

Yoshida H, Okumura K, and Hori R (1990) Contribution of monoamine oxidase (MAO) to the binding of tertiary basic drugs in isolated perfused rat lung. Pharm Res (NY) 7: 398-401.

This article has been cited by other articles:

				Y. E. Savoy, M. A. Ashton, M. W. Miller, F. M. Nedza, D. K. Spracklin, M. H. Hawthorn, H. Rollema, F. F. Matos, and E. Hajos-Korcsok Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation Schizophr Bull, August 14, 2008; (2008) sbn104v1. [Abstract] [Full Text] [PDF]

				X. Liu, C. Chen, and B. J. Smith Progress in Brain Penetration Evaluation in Drug Discovery and Development J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 349 - 356. [Abstract] [Full Text] [PDF]

				K. Venkatakrishnan, E. Tseng, F. R. Nelson, H. Rollema, J. L. French, I. V. Kaplan, W. E. Horner, and M. A. Gibbs Central Nervous System Pharmacokinetics of the Mdr1 P-Glycoprotein Substrate CP-615,003: Intersite Differences and Implications for Human Receptor Occupancy Projections from Cerebrospinal Fluid Exposures Drug Metab. Dispos., August 1, 2007; 35(8): 1341 - 1349. [Abstract] [Full Text] [PDF]

				J. C. Kalvass, T. S. Maurer, and G. M. Pollack Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios Drug Metab. Dispos., April 1, 2007; 35(4): 660 - 666. [Abstract] [Full Text] [PDF]

				M. J. Zamek-Gliszczynski, K.-i. Nezasa, X. Tian, J. C. Kalvass, N. J. Patel, T. J. Raub, and K. L. R. Brouwer The Important Role of Bcrp (Abcg2) in the Biliary Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Mice Mol. Pharmacol., December 1, 2006; 70(6): 2127 - 2133. [Abstract] [Full Text] [PDF]

				X. Liu, B. J. Smith, C. Chen, E. Callegari, S. L. Becker, X. Chen, J. Cianfrogna, A. C. Doran, S. D. Doran, J. P. Gibbs, et al. Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration Drug Metab. Dispos., September 1, 2006; 34(9): 1443 - 1447. [Abstract] [Full Text] [PDF]

				S. Becker and X. Liu EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION Drug Metab. Dispos., May 1, 2006; 34(5): 855 - 861. [Abstract] [Full Text] [PDF]

				S. G. Summerfield, A. J. Stevens, L. Cutler, M. del Carmen Osuna, B. Hammond, S.-P. Tang, A. Hersey, D. J. Spalding, and P. Jeffrey Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1282 - 1290. [Abstract] [Full Text] [PDF]

				A. Gupta, P. Chatelain, R. Massingham, E. N. Jonsson, and M. Hammarlund-Udenaes BRAIN DISTRIBUTION OF CETIRIZINE ENANTIOMERS: COMPARISON OF THREE DIFFERENT TISSUE-TO-PLASMA PARTITION COEFFICIENTS: Kp, Kp,u, AND Kp,uu Drug Metab. Dispos., February 1, 2006; 34(2): 318 - 323. [Abstract] [Full Text] [PDF]

				X. Liu, B. J. Smith, C. Chen, E. Callegari, S. L. Becker, X. Chen, J. Cianfrogna, A. C. Doran, S. D. Doran, J. P. Gibbs, et al. Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1254 - 1262. [Abstract] [Full Text] [PDF]

				A. Doran, R. S. Obach, B. J. Smith, N. A. Hosea, S. Becker, E. Callegari, C. Chen, X. Chen, E. Choo, J. Cianfrogna, et al. THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL Drug Metab. Dispos., January 1, 2005; 33(1): 165 - 174. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.104.001222v1 33/1/175    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maurer, T. S. Articles by Scott, D. O. Search for Related Content PubMed PubMed Citation Articles by Maurer, T. S. Articles by Scott, D. O.